The Long Road to a First: What uniQure's Huntington's Disease Gene Therapy Filing Really Means

On September 2, 2026, uniQure submitted a Biologics License Application to the FDA for ifezuntirgene inilparvovec, known as AMT-130, seeking accelerated approval as the first gene therapy for Huntington's disease. The company simultaneously filed with the UK's Medicines and Healthcare products Regulatory Agency. If the FDA accepts the application for priority review, a decision could come as early as the second quarter of 2027.

That timeline matters because Huntington's disease has been waiting for it for a very long time. There are currently no approved therapies that slow, halt, or reverse the progression of this inherited neurodegenerative disorder. Patients receive treatments for symptoms. Nothing touches the disease itself. AMT-130 would be the first.

What the Disease Does, and What the Drug Tries to Do

Huntington's disease is caused by a CAG repeat expansion in the first exon of the huntingtin gene. That mutation leads to the production of an abnormal huntingtin protein that accumulates in neurons, progressively destroying the brain's ability to control movement, cognition, and behavior. The disease is autosomal dominant, meaning a single copy of the mutated gene is sufficient to cause it. Every child of an affected parent has a 50 percent chance of inheriting it. There is no ambiguity about the cause, no complexity in the genetics, and no approved pharmacological response to the underlying biology.

AMT-130 uses an AAV5 viral vector to deliver an artificial micro-RNA directly into the brain, where it silences the huntingtin gene using uniQure's proprietary miQURE technology. The approach suppresses both the full-length huntingtin protein and the highly toxic exon-1 isoform that is believed to drive much of the neuronal damage. It is administered as a single surgical procedure, with the vector injected directly into the striatum. That delivery method is demanding, but it is also a one-time intervention for a disease that currently requires lifelong management of worsening symptoms with no disease-modifying effect.

The three-year data from uniQure's Phase 1/2 trial, announced in September 2025, showed a 75 percent slowing of disease progression compared to a propensity score-matched external control derived from the Enroll-HD natural history database. That result was striking enough to generate serious regulatory attention, and the FDA has now agreed that those data are sufficient to support an accelerated approval application.

The Regulatory Odyssey Behind the Filing

The path to this filing was not straightforward. In November 2025, the FDA told uniQure it no longer agreed that Phase 1/2 data were adequate to support a BLA submission, reversing a prior agreement on the protocols and statistical analyses the company had used. The reversal came under former FDA Commissioner Marty Makary and former Center for Biologics Evaluation and Research director Vinay Prasad, both of whom had publicly expressed skepticism about the therapy. Makary, in a CNBC interview in February 2026, appeared to describe AMT-130 disparagingly without naming it, referring to a product where researchers drilled a hole in patients' skulls and found no benefit at the end of the randomization period. The characterization was widely understood to be a reference to uniQure's program.

Four months later, both Makary and Prasad had left the agency. The FDA reversed course again, agreeing in June 2026 that the three-year data were sufficient to support an accelerated approval filing. The company submitted in September. The regulatory whiplash that preceded this filing is not a minor footnote. It is a reminder that the path from compelling clinical data to regulatory submission in rare neurological disease is shaped not just by science but by the institutional priorities of the people running the agencies at any given moment.

What the Data Actually Show, and What They Do Not

The 75 percent slowing figure is the headline, but the evidentiary architecture behind it deserves scrutiny. The Phase 1/2 trial enrolled a small number of patients and used an external control rather than a randomized placebo arm. The FDA's accelerated approval pathway allows for approval based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, with confirmatory evidence required post-approval. In this case, the agency has agreed that the three-year data meet that threshold, but the confirmatory trial, which will enroll approximately 200 patients with 2:1 randomization between AMT-130 and standard of care, will need to demonstrate durable clinical benefit to convert the accelerated approval into a full one.

William Blair analysts, who resumed coverage of uniQure following the filing, noted that the trial design aligns with the FDA's published guidance on gene therapies for small populations, which specifically contemplates external controls as appropriate in certain contexts. They estimated peak global sales of $3.2 billion by 2035, a figure that reflects both the severity of the disease and the absence of any competing disease-modifying therapy. The launch will be measured, given the requirement for surgically guided administration, but the commercial opportunity is real.

What This Means for the Huntington's Disease Community

Approximately 30,000 Americans are currently living with Huntington's disease, and another 200,000 are at risk of inheriting it. For that community, the filing of a BLA is not an abstraction. It is the first time in the history of the disease that a company has submitted evidence to a regulatory agency that a single treatment might slow its progression. The clinical data are not perfect, and the regulatory path ahead carries genuine uncertainty. But the filing itself represents a threshold that has never been crossed before.

The broader significance extends beyond Huntington's disease. AMT-130 uses a gene silencing approach delivered via AAV vector to a brain structure that is surgically accessible. If it works, it establishes a proof of concept for addressing neurodegenerative diseases at their genetic root, in conditions where the causal mutation is known and the target tissue can be reached. The huntingtin gene is not the only gene driving a fatal neurodegenerative disease. The lessons from this program, whether it succeeds or requires modification, will inform how the field approaches other conditions where the biology is understood but the therapeutic tools have not yet caught up.

The Regulatory Signal Worth Watching

The FDA's willingness to accept the three-year Phase 1/2 data as the basis for an accelerated approval application, after the institutional turbulence of the past year, is itself a signal. It suggests that the current agency leadership is prepared to apply the accelerated approval framework to rare neurological diseases where the unmet need is severe, the biology is well understood, and the clinical evidence, while limited in scale, is credible and consistent. That posture matters for every company developing gene therapies for rare neurological conditions, and for every patient community waiting to find out whether the regulatory environment will allow the science to reach them.

Whether AMT-130 ultimately receives approval will depend on the FDA's review of the full data package, the outcome of the confirmatory trial, and the manufacturing and safety profile that emerges from broader use. None of those outcomes are guaranteed. What is certain is that the filing has happened, and that for the first time, a regulatory agency is formally evaluating whether a gene therapy can change the course of Huntington's disease. That is a different kind of moment than any that has come before it.